Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, DJ Jonker, F Di Nicolantonio… - Jama, 2010 - jamanetwork.com
Context Patients with metastatic colorectal cancer who have KRAS codon 12–or KRAS
codon 13–mutated tumors are presently excluded from treatment with the anti–epidermal …
codon 13–mutated tumors are presently excluded from treatment with the anti–epidermal …
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
W De Roock, D Jonker, F DI NICOLANTONIO… - JAMA, 2010 - iris.unito.it
CONTEXT. Patients with metastatic colorectal cancer who have KRAS codon 12-or KRAS
codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal …
codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal …
Association of KRAS p. G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab.
W De Roock, DJ Jonker… - JAMA: Journal of …, 2010 - search.ebscohost.com
The article presents information on a study which determined whether KRAS codon 13
mutations are associated with improved outcome following cetuximab treatment than …
mutations are associated with improved outcome following cetuximab treatment than …
Association of KRAS p. G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
W De Roock, H Piessevaux, DJ Jonker… - JAMA: the journal of …, 2010 - dial.uclouvain.be
Context Patients with metastatic colorectal cancer who have KRAS codon 12-or KRAS
codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal …
codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal …
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
W De Roock, DJ Jonker, F Di Nicolantonio… - JAMA, 2010 - europepmc.org
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory
metastatic colorectal cancer treated with cetuximab. - Abstract - Europe PMC Sign in | Create an …
metastatic colorectal cancer treated with cetuximab. - Abstract - Europe PMC Sign in | Create an …
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, D Jonker… - JAMA-Journal of …, 2010 - researchnow.flinders.edu.au
Context: Patients with metastatic colorectal cancer who have KRAS codon 12-or KRAS
codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal …
codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal …
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, DJ Jonker, F Di Nicolantonio… - JAMA, 2010 - research.monash.edu
Context: Patients with metastatic colorectal cancer who have KRAS codon 12-or KRAS
codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal …
codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal …
[PDF][PDF] Association of KRAS p. G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
JAMA, 2010 - publicationslist.org
Objective To test the hypothesis that KRAS codon 13 mutations are associated with a better
outcome after treatment with cetuximab than observed with otherKRASmutations. Design …
outcome after treatment with cetuximab than observed with otherKRASmutations. Design …
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, DJ Jonker, F Di Nicolantonio… - JAMA, 2010 - air.unimi.it
Context: Patients with metastatic colorectal cancer who have KRAS codon 12-or KRAS
codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal …
codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal …
[引用][C] Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
DE ROOCK - JAMA, 2010 - cir.nii.ac.jp
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory
metastatic colorectal cancer treated with cetuximab | CiNii Research CiNii 国立情報学研究所 …
metastatic colorectal cancer treated with cetuximab | CiNii Research CiNii 国立情報学研究所 …